ORIGINAL ARTICLE



Differential outcomes for frontal versus posterior demyelination in childhood cerebral adrenoleukodystrophy

Ashish O. Gupta¹ | David R. Nascene² | Ryan Shanley³ | Daniel L. Kenney-Jung⁴ | Julie B. Eisengart¹ | Troy C. Lund¹ | Paul J. Orchard¹ | Elizabeth I. Pierpont¹

¹Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA

²Department of Radiology, University of Minnesota, Minneapolis, Minnesota, USA

³Bioinformatics and Biostatistics Core, University of Minnesota, Minneapolis, Minnesota, USA

⁴Department of Neurology, University of Minnesota, Minneapolis, Minnesota, USA

Correspondence

Elizabeth I. Pierpont, Department of Pediatrics, University of Minnesota, Division of Clinical Behavioral Neuroscience, 2450 Riverside Avenue, RPB Suite 550, Minneapolis, MN, 55454, USA.

Email: pier0053@umn.edu

Funding information

1 |

This research was supported by the National Institutes of Health's National Center for Advancing Translational Sciences, grants KL2TR002492 and UL1TR002494, and by the University of Minnesota Department of Pediatrics. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Abstract

In the most common variant of childhood cerebral adrenoleukodystrophy (cALD), demvelinating brain lesions are distributed predominately in parietooccipital white matter. Less frequently, lesions first develop in frontal white matter. This matched cohort study examined whether outcomes after standard treatment with hematopoietic cell transplantation (HCT) differ in patients with early stage frontal lesions as compared to parieto-occipital lesions. Retrospective chart review identified seven pediatric patients with frontal cALD lesions and MRI severity score < 10 who underwent a single HCT at our center between 1990 and 2019. Concurrent MRI, neurocognitive and psychiatric outcomes at last comprehensive follow-up (mean 1.2 years; range 0.5-2.1 years) were compared with a group of seven boys with the parieto-occipital variant matched on pre-HCT MRI severity score. Both groups showed similar rates of transplant complications and radiographic disease advancement. Neurocognitive outcomes were broadly similar, with more frequent working memory deficits among individuals with frontal lesions. Psychiatric problems (hyperactivity, aggression, and atypical behavior) were considerably more common and severe among patients with frontal lesions. Aligned with the critical role of the frontal lobes in emotional and behavioral regulation, functional disruption of self-regulation skills is widely observed among patients with frontal lesions. Comprehensive care for cALD should address needs for psychiatric care and management.

KEYWORDS

adrenoleukodystrophy, cerebral, cognition, MRI, psychiatric, stem cell transplantation

Communicating Editor: Carlos Ferreira

Childhood cerebral adrenoleukodystrophy (cALD) is a rare X-linked, progressive demyelinating disorder affecting

INTRODUCTION

young boys. Hematopoietic cell transplantation (HCT) is the current standard of care to halt cALD progression with an overall survival of $\sim 80\%$.¹ Even when HCT occurs early in the disease course, individuals with cALD commonly experience neurocognitive deficits and/or psychiatric disturbance following treatment.² Pre-treatment MRI severity and

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any

medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2021 The Authors. Journal of Inherited Metabolic Disease published by John Wiley & Sons Ltd on behalf of SSIEM.

Click here to access the podcast for this paper.

TABLE 1 Study cohort characteristics



Baseline variablesMean (SD): rangeMean (SD): rangeAgs at transplant (years)11.8 (2.5): 9-167.5 (1.6): 5-10Pre-HCT Loes MRI severity score5.6 (1.7): 3.85.6 (2.0): 3.9RoseNNWhite/Caucasian66Biack/Alrican American10.0Asian01Transplant variablesFrit/Cy/ARG400Bu/Cy 4 Alemtuzumab or ATG27.0Bu/Cy 4 Alemtuzumab or ATG20.0Graft sourceTransplant variables21.0Graft source21.0Graft source21.0UCB22.01.0Graft sourceVCG22.01.0UCB21.01.0UCB21.01.0UCB21.01.0UCB21.01.0UCB21.01.0Graft Source1.01.0UCB21.01.0Sibling1.01.0UCB1.01.0UCB2.01.0UCB2.01.0UCB2.01.0CSA/Mr1.01.0Sibling1.01.0Placket (day)40(40.11.0Placket (day)40(40.2)1.0Placket (day)40(40.2)1.0Graft Source1.01.0 <th>Demographics</th> <th>Frontal ($N = 7$)</th> <th>Parieto-occipital ($N = 7$)</th>	Demographics	Frontal ($N = 7$)	Parieto-occipital ($N = 7$)
Age at transplant (years)118 (2.5): 9-167.5 (1.6): 5-10Pre-IC Loes MRI severity score5.6 (1.7): 3-85.5 (2.0): 3-9RaceNNNWhite/Cuessian661Back/African American101Transplant variablesConditioningTBI/C/y A160400-Back/African American20Back/African American2Back/African American2Back/African American1Back/African American2Back/African American2Back/African American5Back/African American2Back/African American2Back/African2<			
Pre-IIC Lose MRI sevenity score56 (J.); 3855 (J.0); 39RackNNRackNNBlack/Arican American10Black/Arican American10Arian01TurrysterIITurrysterIITurrysterIITurrysterIITurrysterIITurrysterIITurrysterIITurrysterIITurrysterIITurrysterIITurrysterIITurrysterIIBone marrowSISiblingIIOrall DurelatedIUrelatedII <td>Age at transplant (years)</td> <td></td> <td></td>	Age at transplant (years)		
RecNNWh(Caucaian6Black/African American0Asian0Tarsplant variables1Transplant variables-rTBI/Cy/ATG40Bu/Cy E Alentuzumab or ATG2Bu/Flu10Bu/Flu10Bu/Cy E Alentuzumab or ATG2Bu/Flu10Graft source-rtmanching21UCB21UCB21Graft source-1Cyclic21Sibling21UCB21Cyclic21Cyclic21Cyclic21Graft source-1Cyclic21UCB21Cyclic21Cyclic21Cyclic21Cyclic21Cyclic21Cyclic31Cyclic31Cyclic11Cyclic11Cyclic11Cyclic11Cyclic21Cyclic11Cyclic11Cyclic11Cyclic11Cyclic11Cyclic11Cyclic11Cyclic11 <td>-</td> <td></td> <td></td>	-		
White/Caucasian66Black/African American1Black/African American1Asian01TransplartConditoringTransplart VariablesConditoringfTBI/Cy/ATG40Bu/Plu10Bu/Plu10Graft sourceBone marrow522Bone marrow520UCB220Urelated220UCB220Graft sourceBone marrow533Urelated223Urelated233Urelated233Urelated533Urelated533Graft SourceGraft SourceCycle Addition33Graft Source-3Graft Source-3Cycle Addition4Graft Source-Graft Source-Graf			
Back/African American10Asin01Asin01TRI/Cy/ATG40Br/Cy/ATG27Br/Cy/ATG27Br/Cy/ATG20Br/Cy/ATG22Brommow52Graft source21Urble table23Urble table23Urble table23Brommow53UCB23UCB565/6335/6235/6336/6335/6336/7335/6336/8335/9336/9336/9336/9335/9336/9336/9336/9336/9336/9336/9336/9337/94310000033933933933933933933933933933933	White/Caucasian		
Asia01Tarsplart variables.rtraplart variables.rtraplart variables.rtraplart variables.rtraplart variables.pring trapplart variables.prin			0
Timple transmitConditioningConditioningIPI/Cy/ATG4.0Bu/Cy ± Alentuzumabor ATG2.0Bu/Cy ± Alentuzumabor ATG2.0Urelace2.0Urelace2.0Color <td< td=""><td></td><td>0</td><td>1</td></td<>		0	1
ConditioningfTB/Cy/ATG40BU/Cy Alemuzumab or ATG27BU/Dy Alemuzumab or ATG27JURu127Burnarow211Unrelated231URI233URI233JUR233JUR233JUR233JUR233JUR233JUR233JUR233JUR333			
fTBI/CY/ATG 4/emtaumab or ATG 2Bu/Pu 2000 7Bu/Pu 2000 7Grafusure 7Grafusure 7Grafusure 7Jone marrow 8Grafusure 7Jone marrow 8Jone 8			
Bu/Og Alemtuzumab or ATG27Bu/Og Alemtuzumab or ATG1Born marrow5Jone marrow2Normarrow2Sibling2Jone marrow3Urelated3UCB2Sibling2JCG3JCG3Sibling3JCG3JCG3Sibling3JCG3JCG3Sibling3JCG3JCG3JCG3JCG3JCARD4Sibling4JCARD3JCARD3JCARD4JCARD3		4	0
Birlin10Graftsource52Bone marrow52Bone marrow21Jurelata23Urelated33UB33UB23Jurelata23Jurelata33Jurelata23Jurelata33Jurelata33Jurelata33Jurelata33Jurelata33Jurelata43Jurelata43Jurelata33Jurelata33Jurelata33Jurelata43Jurelata43Jurelata33Jurelata <td></td> <td>2</td> <td>7</td>		2	7
Bone marrow52Sibling21Jurelated33UCB25H			0
Sibling21Sibling31Unclated33UCB233H⊥matching2336 ⁴ 533356 ⁴ 2 ⁴ 0136 ⁴ 53336 ⁴ 33336 ⁴ 53336 ⁴ 56336 ⁴ 63336 ⁴ 63336 ⁴ 61136 ⁴ 61336 ⁴ 63336 ⁴ 63336 ⁴ 73336 ⁴ 101336 ⁴ 101336 ⁴ 101136 ⁴ 101116 ⁴ 101 <td>Graft source</td> <td></td> <td></td>	Graft source		
Sibling21Jurelated33UR23JUR23JUR33Job23Job23Job33Job		5	2
Index31UCB25HA matching5565215/62114/6011CSA/Ped423CSA/Ped342CSA/Ped011CSA/Ped011CSA/Ped011CSA/Ped404374043740437CSA/MK011CSA/MK140457402371742(2871)Actrophil (days)402437142(2871)42(2871)acVHDNatorenee33Grade 1-2233Grade 1-2101Grade 3-4101CVHD011Crade 3-4233Grade 3-4233Grade 3-4101CVHD011Crade 3-4233Grade 3-4111CVHD111CVHD111CVHD111CVHD111CVHD111CVHD111CVHD111CVHD111CVHD111CVHD111CVHD111C	Sibling	2	1
HL matching6/655/62°114/60GVHD prophylaxis2CSA/Pred4CSA/Mr2CSA/Mr0CSA/Mr0EyraftmentMedian (range)Neutrophil (days)4/045)Platets (days)4/0452)Grada 1-20Grada 1-21Grada 1-20Grada 1-20Grada 1-20Grada 1-20Grada 1-20Grada 1-21Difference1Strurvixil, Alive010Strurvixil, Alive2°Courburd120(S); rangeFollow-up evaluation120(S); rangeLes MRI severity score70(29; 4-101)MRI severity score70(29; 4-101)MI serviciation6Minulant medication6Minulant medication1Other ADHD medication1Other ADHD medication1Struct Courburd1Struct Courburd1Struct Courburd1Struct Courburd1Minulant medication6Struct Courburd1Struct Courburd1Struct Courburd1Struct Courburd1Struct Courburd1Struct Courburd1Struct Courburd1Struct Courburd1Struct Courburd1Struct Courburd	-	3	1
6650505050562°14601CWDrophylaxis42CSA/Prod42CSA/MMF01CSA/MMF01EyraftmentMedian (range)Median (range)Neutrophil (days)40(23217)42(28-71)Plateks (days)4033Grade 1-2233Grade 1-2233Grade 3-4101CVHD011CVHD2°01Grade 1-22°01Grade 1-22°01Grade 1-22°01Grade 1-21011CVHD122°1CVHD2°11CVHD2°11CVHD2°11CVHD2°11Fullw-up evaluation2°11V=up evaluation120(6).05-2.12(0.5).08-2.1Lors MR severity score70(29).4-1084(40).4-16MINdendication611Minulan medication61Minulan medication11Minulan medication11Minulan medication11Minulan medication11Minulan medication11Minulan medication11Minulan medication1	UCB	2	5
6650505050562°14601CWDrophylaxis42CSA/Prod42CSA/MMF01CSA/MMF01EyraftmentMedian (range)Median (range)Neutrophil (days)40(23217)42(28-71)Plateks (days)4033Grade 1-2233Grade 1-2233Grade 3-4101CVHD011CVHD2°01Grade 1-22°01Grade 1-22°01Grade 1-22°01Grade 1-21011CVHD122°1CVHD2°11CVHD2°11CVHD2°11CVHD2°11Fullw-up evaluation2°11V=up evaluation120(6).05-2.12(0.5).08-2.1Lors MR severity score70(29).4-1084(40).4-16MINdendication611Minulan medication61Minulan medication11Minulan medication11Minulan medication11Minulan medication11Minulan medication11Minulan medication11Minulan medication1	HLA matching		
4/601GVHD prophylaxis42CSA/Pred42CSA/MF34CSA/MK01ExgrafmentMedian (range)Median (range)Neutrophil (days)4/045217142(28-71)av-HDN22(28-71)of crade 1-223of crade 3-410crade 3-42 ^b 0craft failure2 ^b 0craft failure2 ^b 0cy-ury parkungiantMen (SD); rangeMen (SD); rangefollow-up evaluation12(06); 0.5-2.112(05); 0.8-2.1tots MR severity scoreN34(40); 416stimulant medication61Minulant medication61Minulant medication10Minulant medication <td></td> <td>5</td> <td>5</td>		5	5
GVHD prophylaxisSA/Pred4CSA/Pred42CSA/MAF34CSA/MAF01ExgraftmentMedia (narge)Media (narge)Neutrophil (days)4094321706 (11-35)Patelets (days)49(32-217)42(28-71)Grade 1-2N33Grade 3-410CVHD01CVHD01Grade 3-42 ^b 0CVHD2 ^b 0Syster survival, Alive7 ^c 7Follow-up evaluationMean (SD); range12(05); 0.8-2.1Ivan Streiger Str	5/6	2^{a}	1
CSA/Pred42CSA/MIF34CSA/MIX01FraftmentMedia (range)Media (range)Neutrophil (days)4(945)6(1135)Patelets (days)40(3217)42(827)Grade 1-203Grade 3-410C-WT01C-WT00C-WT01Taftafure2 ^b 0T-Taftafure2 ^b 0V-Turyenyaluation7 ^c 7V-Turyenyaluation12(05)05-2112(05)05-21V-Turyenyaluation70(29)-4104(20)-21V-Turyenyaluation70(29)-4104(20)-21V-Turyenyaluation12(05)05-213(10)-31V-Turyenyaluation612(05)05-21Stimulian medication61Manantendication61Manantendication11Manantendication11Manantendication11Manantendication11Manantendication11Manantendication11Manantendication11Manantendication11Manantendication11Manantendication11Manantendication11Manantendication11Manantendication11Manantendication11Manantendication11Manantendication1 <td< td=""><td>4/6</td><td>0</td><td>1</td></td<>	4/6	0	1
SA/MMF34CSA/MX01FraftmentMedia (range)Media (range)Neutrophil (days)14 (-45)16 (1-3)Platels (days)40 (32)2(28-7)Grade 1-2NNGrade 1-223Grade 3-410C-VT01Grade 3-42 ¹ 0C-VT01Grade 1-22 ¹ 0Grade 3-42 ¹ 0C-VT01C-VT01C-VT101C-VT12 (05), 12 (05)	GVHD prophylaxis		
KSA/Mtx01KMtxMedia (range)Media (range)Indersphil (days)14 (945)16 (1-35)Platets (days)40 (23 - 21)42 (28 - 71)ImportNNNImport111	CSA/Pred	4	2
InstructionMedian (range)Median (range)Neutrophil (days)14 (9-45)16 (11-35)Platelets (days)49 (23-217)42 (28-71)aGrade 1-2NNGrade 3-423Grade 3-410Grade 3-401Grade 3-401Grade 3-401Grade 3-401Grade 3-401Grade 3-401Grade 3-401Grade 3-4120 (S)	CSA/MMF	3	4
Neutrophil (days) 14 (9-45) 16 (11-35) Platelets (days) 49 (32-217) 42 (28-71) aGvHD N N Grade 1-2 2 3 Grade 3-4 1 0 cGvHD 0 1 Grade 3-4 2 ^b 0 Grade 1-2 2 ^b 0 Grade 3-4 0 1 Grade 3-4 0 1 Grade 3-4 0 1 Grade 3-4 1 0 Grade 3-4 0 1 Grade 3-4 1 0 Follow-up explating Alive 7 ^c 7 Follow-up explaution Man (SD); range 12 (0.5); 0.8-2.1 Lees MRI severity score 70 (2.9); 4-10 84 (4.0); 4-16 Psychiatric medication 6 1 1	CSA/Mtx	0	1
Platelets (days)49 (23-217)42 (28-71)aGvHDNNGrade 1-223Grade 3-410cGvHD01Graft failure2 ^b 05-year survival, Alive7 ^c 7Follow-up evaluationMean (SD); rangeMean (SD); rangeYears since HCT7.0 (2.9); 4-108.4 (4.0); 4.16Loes MRI severity scoreNNPsychiatric medication61Other ADHD medication10	Engraftment	Median (range)	Median (range)
a r G rad 1-2NNG rad 1-223G rad 3-410c r C r C r01C r C r C r C r2 ^b 03 r C r	Neutrophil (days)	14 (9-45)	16 (11-35)
Grade 1-223Grade 3-410cd-401cd-T01Grade 3-42 ^b 0Grade 3-42 ^b 0Grade 3-42 ^b 0Grade 3-42 ^b 0Follow-10 pevaluation7 ^c 7Follow-10 pevaluation12(06);05-2.112(0.5);0.8-2.1Follow-10 pevaluation70(29);4-1084(40);4-16Follow-10 pevaluationNNFollow-10 pevaluation61Stimulan medication10	Platelets (days)	49 (23-217)	42 (28-71)
Grade 3-410Grade 3-401cGvHD01Graft failure2 ^b 05-year survival, Alive7°7Follow-up evaluationMan (SD); rangeMan (SD); rangeYears since HCT1.2 (0.6); 0.5-2.11.2 (0.5); 0.8-2.1Loes MRI severity score70 (2.9); 4-108.4 (4.0); 4-16Stimulant medication61Other ADHD medication10	aGvHD	Ν	Ν
cGvHD01Graft failureb05-year survival, Alivec7°Follow-up evaluationMean (SD); rangeMean (SD); rangeYears since HCT1.2 (0.6); 0.5–2.11.2 (0.5); 0.8-2.1Loes MRI severity score70 (2.9); 4–1084 (4.0); 4-16Psychiatric medication61Munant medication61Other ADHD medication10	Grade 1–2	2	3
Graft failure2b05-year survival, Alive7c7cFollow-up evaluationMean (SD); rangeMean (SD); rangeYears since HCT1.2 (0.6); 0.5-2.11.2 (0.5); 0.8-2.1Loes MRI severity score7.0 (2.9); 4-108.4 (4.0); 4-16Psychiatric medicationNNStimulant medication61Other ADHD medication10	Grade 3–4	1	0
5-year survival, Alive7c7cFollow-up evaluationMean (SD); rangeMean (SD); rangeYears since HCT1.2 (0.6); 0.5–2.11.2 (0.5); 0.8-2.1Loes MRI severity score7.0 (2.9); 4–108.4 (4.0); 4-16Psychiatric medicationNNStimulant medication61Other ADHD medication10	cGvHD	0	1
Follow-up evaluationMean (SD); rangeMean (SD); rangeYears since HCT1.2 (0.6); 0.5-2.11.2 (0.5); 0.8-2.1Loes MRI severity score7.0 (2.9); 4-108.4 (4.0); 4-16Psychiatric medicationNNStimulant medication61Other ADHD medication10	Graft failure	2 ^b	0
Years since HCT 1.2 (0.6); 0.5–2.1 1.2 (0.5); 0.8–2.1 Loes MRI severity score 7.0 (2.9); 4–10 8.4 (4.0); 4-16 Psychiatric medication N N Stimulant medication 6 1 Other ADHD medication 1 0	5-year survival, Alive	7 ^c	7
Loes MRI severity score7.0 (2.9); 4-108.4 (4.0); 4-16Psychiatric medicationNNStimulant medication61Other ADHD medication10	Follow-up evaluation	Mean (SD); range	Mean (SD); range
Psychiatric medicationNNStimulant medication61Other ADHD medication10	Years since HCT	1.2 (0.6); 0.5–2.1	1.2 (0.5); 0.8-2.1
Stimulant medication61Other ADHD medication10	Loes MRI severity score	7.0 (2.9); 4–10	8.4 (4.0); 4-16
Other ADHD medication 1 0	Psychiatric medication	Ν	Ν
	Stimulant medication	6	1
Sleep medication 2 0	Other ADHD medication	1	0
	Sleep medication	2	0

(Continues)

TABLE 1 (Continued)

Demographics	Frontal ($N = 7$)	Parieto-occipital ($N = 7$)
Neurocognitive impairment ^d		
Verbal reasoning	3	2
Visual reasoning	2	0
Working memory	4	0
Processing speed	2	3

Abbreviations: aGvHD, acute graft vs host disease; ATG, anti-thymocyte globulin; Bu, busulfan; cGvHD, chronic graft vs host disease; CSA, cyclosporine; Cy, cyclophosphamide; fTBI, fractional total body irradiation; Flu, fludarabine; HCT, hematopoietic cell transplant; HLA, human leukocyte antigen; MMF, mycophenolate mofetil; Mtx, methotrexate; MRI, magnetic resonance imaging; UCB, Umbilical cord blood.

^aOne patient received double UCB both 5/6 matching.

^bOne patient met the criteria for primary graft failure (absence of neutrophil engraftment by day 42 post-HCT) but subsequently engrafted. The second patient had secondary graft failure with an autologous recovery at day 276 post-HCT. Both patients are alive and neither underwent a second HCT.

^cOne patient died 9.7 years after HCT due to cardiorespiratory arrest secondary to disease progression.

^dNeurocognitive impairment is defined as a score of <70 on Wechsler IQ scales.




FIGURE 1 Loes MRI severity scores were obtained prior to treatment and at a mean of 1.2 years after hematopoietic stem cell transplantation. Connected lines represent the change in scores for individual patients with frontal or parietal-occipital demyelinating lesions

neurocognitive status are well-established predictors of treatment response,³⁻⁵ but examination of the impact of the lesion location on outcomes has been limited by small sample sizes. Typically, lesions first develop in the splenium of corpus callosum with subsequent expansion into parieto-occipital white matter (POWM). In about 15-17% of cases, cALD emerges in the genu of corpus callosum expanding to frontal white matter (FWM).^{6,7} The FWM variant has been suggested to be an unfavorable risk factor for disease progression after treatment.^{4,6} Given the possibility of differential treatment response and the vastly different functions supported by the frontal vs posterior regions of the brain,

this matched case series investigated the impact of lesion location on treatment response and neuropsychological outcomes.

2 | METHODS

Ethics approval for this retrospective analysis was obtained from the University of Minnesota Institutional Review Board. Brain MRIs from pre-treatment evaluations were reviewed for all 158 patients who underwent HCT at our center between January 1, 1990 and December 31, 2019.





FIGURE 2 Longitudinal T2 FLAIR axial images for two patients with cerebral ALD lesions affecting (A) frontal white matter and (B) parietal-occipital white matter. MRIs for both patients received the same Loes MRI severity score of 4 at the time of HCT

Demyelination pattern and MRI severity were determined using the Loes scale.⁸ The following inclusion criteria were applied to identify the FWM cohort: under age 18 years at the time of HCT; Loes score < 10; FWM demyelination without POWM disease; treated with a single allogeneic HCT. The seven patients meeting these inclusion criteria were matched to seven patients with POWM disease based on closest possible pre-HCT Loes score and lack of FWM involvement. A flow chart describing study selection is available in DATA S1.

Demographic data and transplant variables are presented in Table 1. HCT followed previously described institutional procedures; neutrophil and platelet engraftment, graft-vs-host disease and graft failure were determined based on reported HCT criteria.⁹ Follow-up MRI severity scores, neurocognitive testing and psychiatric scores from the most recent comprehensive clinical evaluation were obtained from chart review (mean 1.2 years post-HCT, range 0.5-2.1 years). To analyze comparable data for each matched FWM-POWM pair, scores were used from the most recent visits in which data were available for both patients at the same time point (\pm 3 months). Consistent with published methods,¹⁰ verbal reasoning, visual reasoning, working memory, and processing speed were measured with the Wechsler intelligence scales. Psychiatric symptoms were assessed via caregiver ratings on clinical scales of the Behavior Assessment Scale for Children (BASC), a well-validated measure of pediatric psychopathology. Severe impairment was defined by neurocognitive and psychiatric scores ≥ 2 SDs from the normative mean. A decline of >7.5 points on a Wechsler scale was used to identify a minimum clinically important difference from pre- to post-HCT.¹¹ Clinical progress notes were reviewed to obtain additional detailed information about psychiatric concerns and psychoactive medications prescribed. Statistical analysis focused on descriptive statistics with confidence intervals and Kaplan-Meier calculations for overall survival. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). Written informed consent to participate in clinical outcomes research was obtained from parents/guardians of patients included in this study.

3 | RESULTS

The 5-year overall survival was 100% in both groups, with a similar rate of transplant-related complications including graft-vs-host disease (Table 1). One late death was observed in the FWM cohort at 9.6 years post-HCT due to cardiore-spiratory arrest secondary to disease progression. Post-HCT change in Loes MRI severity scores during the study period, illustrated in Figure 1, did not differ reliably in the POWM as compared to the FWM group (mean difference: 1.4, 95%



Region 🛱 Frontal variant 🛱 Parieto-occipital variant

FIGURE 3 Neurocognitive outcomes of patients with frontal and parietal-occipital demyelination variant of cerebral ALD after hematopoietic stem cell transplantation. Wechsler IQ scales have a normative mean of 100 ± 15 . Gray shading depicts scores in the average range. Boxplots represent the interquartile range for each outcome with a vertical line at the median. Outliers are denoted with dots, and the remaining range of each outcome is shown with horizontal lines

CI: -1.6, 4.4). Figure 2 displays representative MRI images from two patients with FWM or POWM lesions, with pre-HCT images and follow up out to 3 years after treatment. Neurocognitive outcomes were also broadly similar (Figure 3). In both groups, 5/7 boys (71%) exhibited clinically meaningful decline in \geq 1 neurocognitive domain from pre-HCT to follow-up. Development of severe impairment in working memory, which requires significant focus and attention to retain information for brief periods, was more frequent in the boys with FWM (4/7) as compared to POWM (0/7) lesions.

Clinical psychiatric concerns were more evident at follow up in the FWM group. Stimulant medication was prescribed to 6/7 (86%) FWM patients to address concerns with poor attention, impulse control and/or behavior regulation, as compared to 1/7 (14%) POWM patients. All four FWM patients with available caregiver ratings exhibited severe hyperactivity, and 3/4 demonstrated severely atypical behavior (eg, acting out of touch with reality, confused or disorganized speech, bizarre behaviors), whereas none of the POWM patients showed severe psychiatric symptoms (Figure 4). Neuropsychological evaluation reports provided evidence of severe behavioral problems for the three FWM patients without available caregiver ratings. One patient with FWM disease (age 11) was unable to remain seated for more than a few seconds during neuropsychological assessment. His clinical notes described poor social boundaries, near-constant talking, tangential speech, and destructive behaviors (eg, bending puzzle pieces, ripping pages out of test books), consistent with parent and teacher interview data indicating severe behavioral problems. Inattention, irritability and




FIGURE 4 Caregiver ratings of psychiatric symptoms following hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy. T-scores on clinical scales of the Behavior Assessment System for Children (BASC) have a normative mean of 50 ± 10 . Higher scores indicate more severe symptoms. Connected markers depict scores for individual patients



behavioral outbursts were noted for another patient (age 11), and the third patient (age 17) exhibited physically aggressive and oppositional behaviors with family members.

4 | DISCUSSION

This investigation revealed greater risk for severe psychiatric and working memory impairment when demyelinating cALD lesions were located in FWM, a critical brain region for regulation of thoughts, emotions and behavior. As compared to patients with the more common POWM variant of cALD, boys with FWM lesions were more likely to develop inattentive, hyperactive, aggressive and severely atypical behaviors, and to require medication to treat psychiatric symptoms. These results highlight the importance of comprehensive post-HCT care to address the behavioral health manifestations of cALD. Such severe psychiatric concerns exert wide-ranging effects on academic performance, task completion, social relationships, and day-to-day function.

Although pronounced psychiatric impairment was more widely observed in the FWM cohort, the current study failed to replicate a previous report suggesting greater risk for progression of cALD among FWM patients as compared to POWM patients. Kühl and colleagues reported a higher risk for fatal disease progression among patients with FWM lesions when Loes score was ≥ 4 (n = 4); below this threshold, outcomes were more favorable (n = 2).⁴ While the study by Kühl et al. involved a longer follow-up period, the changes among those patients who progressed occurred within a time frame comparable to the present study. With a casematching design, our investigation found that post-HCT advancement of MRI severity scores was no greater in the FWM group than the POWM group. Although 6/7 patients (86%) in our cohort had pre-HCT scores between 4 and 9, just one FWM patient (pre-HCT score of 6) died of eventual disease progression. Our finding of more comparable HCT survival and MRI progression in the FWM and POWM cohorts when MRI severity score < 10 is consistent with an earlier study by Loes et al. showing equivalent rates of disease progression in non-transplanted patients with FWM and POWM lesions.⁶ Taken together with recent studies, our findings suggest that over-reliance on MRI severity "cutoff" scores to aid in prediction of favorable vs unfavorable outcomes may oversimplify the factors contributing to treatment response in this complex demyelinating disease. MRI severity, the neurocognitive status of a patient at the time of HCT, treatment-related variables, and the location of the lesion may all impact the likelihood of neurological and neuropsychological morbidities in the years following treatment.^{4,5,12}

This retrospective study spanned over three decades with different conditioning regimens, GVH prophylaxis and potential neurotoxicity, which could have adversely affected neurocognitive function. Since moderate reduction in memory is a potential neurocognitive side effect of total body irradiation (TBI),^{13,14} use of fractionated could TBI conditioning have contributed neurocognitive deficits in two of the four patients with FWM lesions who experienced severe working memory impairment. Nevertheless, effects of treatment regimens are unlikely to explain the range of symptoms observed in our cALD patients. Psychiatric disturbance involving hyperactivity and severely atypical behavior is not commonly reported among survivors of HCT,15 implicating a more direct association with FWM demyelinating lesions.

The results of this investigation provide evidence that along with MRI severity and neurocognitive status at the time of treatment, lesion location should be considered among risk factors for neurocognitive and psychiatric morbidities. Whether HCT remains the standard of care for early cALD or is replaced by emerging gene therapy approaches,¹⁶ identification of prognostic factors that facilitate comprehensive care are critical. Care models should address the need for psychiatric resources for children and families, with recognition of differential risk based on lesion location.

ACKNOWLEDGMENTS

The authors wish to acknowledge the patients and their families who participated in these evaluations. We thank Elsa Shapiro for historical design of neuropsychological assessment methods, and are grateful for research assistance from Samuel Kroening, Sabrina Bui, Erin McCoy, and Julene Maniak.

CONFLICT OF INTEREST

Ashish Gupta, Ryan Shanley, Daniel Kenney-Jung, and Elizabeth Pierpont declare that they have no conflict of interest. David Nascene consults with Biogen and World-Care Clinical. Julie Eisengart served as an advisory board member for bluebird bio. Troy Lund and Paul Orchard receive research support from bluebird bio. Guarantor: Elizabeth I. Pierpont.

AUTHOR CONTRIBUTIONS

Ashish Gupta: study concept and design, data acquisition, analysis, and interpretation of data, and drafting and revising the manuscript. **David Nascene**: MRI interpretation and scoring and revising the manuscript for important intellectual content. **Ryan Shanley**: analysis and interpretation of data, drafting figures, and drafting 1440 WILEY_JIMD

MD 🖏 ssiem _

and revising the manuscript. Daniel Kenney-Jung: data acquisition, interpretation of data, and revising the manuscript for important intellectual content. Julie Eisengart: data acquisision, interpretation of data, and drafting and revising the manuscript. Troy Lund: data acquisition, interpretation of data, and revising the manuscript for important intellectual content. Paul Orchard: data acquisition, interpretation of data, and revising the manuscript for important intellectual content. Elizabeth Pierpont: study concept and design, data acquisition, analysis and interpretation of data, drafting/revising the manuscript and study supervision. Elizabeth Pierpont: responsibility for the work and the conduct of the research, has access to the data, and controlled the decision to publish.

ETHICS APPROVAL

This study was approved by the University of Minnesota Institutional Review Board under the following protocol: STUDY00002247.

ORCID

Elizabeth I. Pierpont https://orcid.org/0000-0001-7555-8613

REFERENCES

- 1. Raymond GV, Aubourg P, Paker A, et al. Survival and functional outcomes in boys with cerebral adrenoleukodystrophy with and without hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant.* 2019;25(3):538-548.
- 2. Pierpont EI, Nascene DR, Shanley R, et al. Neurocognitive benchmarks following transplant for emerging cerebral adrenoleukodystrophy. *Neurology*. 2020;95(5):e591-e600.
- 3. Peters C, Charnas LR, Tan Y, et al. Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. *Blood.* 2004;104(3):881-888.
- Kühl JS, Kupper J, Baque H, et al. Potential risks to stable long-term outcome of allogeneic hematopoietic stem cell transplantation for children with cerebral X-linked adrenoleukodystrophy. *JAMA Netw Open.* 2018;1(3):e180769.
- Pierpont EI, McCoy E, King KE, et al. Post-transplant adaptive function in childhood cerebral adrenoleukodystrophy. *Ann Clin Transl Neurol.* 2018;5(3):252-261.
- Loes DJ, Fatemi A, Melhem ER, et al. Analysis of MRI patterns aids prediction of progression in X-linked adrenoleukodystrophy. *Neurology*. 2003;61(3):369-374.

- Liberato AP, Mallack EJ, Aziz-Bose R, et al. MRI brain lesions in asymptomatic boys with X-linked adrenoleukodystrophy. *Neurology*. 2019;92(15):e1698-e1708.
- Loes DJ, Hite S, Moser H, et al. Adrenoleukodystrophy: a scoring method for brain MR observations. *AJNR Am J Neuroradiol*. 1994;15(9):1761-1766.
- Gupta A, Downey M, Shanley R, et al. Reduced-toxicity (BuFlu) conditioning is better tolerated but has a higher second transplantation rate compared to myeloablative conditioning (BuCy) in children with inherited metabolic disorders. *Biol Blood Marrow Transplant*. 2020;26(3):486-492.
- Pierpont EI, Eisengart JB, Shanley R, et al. Neurocognitive trajectory of boys who received a hematopoietic stem cell transplant at an early stage of childhood cerebral adrenoleukodystrophy. *JAMA Neurol.* 2017;74(6):710-717.
- 11. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. *Med Care*. 2003;41(5):582-592.
- 12. Miller WP, Rothman SM, Nascene D, et al. Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report. *Blood.* 2011;118(7):1971-1978.
- Peper M, Steinvorth S, Schraube P, et al. Neurobehavioral toxicity of total body irradiation: a follow-up in long-term survivors. *Int J Radiat Oncol Biol Phys.* 2000;46(2):303-311.
- Willard VW, Leung W, Huang Q, Zhang H, Phipps S. Cognitive outcome after pediatric stem-cell transplantation: impact of age and total-body irradiation. *J Clin Oncol.* 2014;32(35):3982-3988.
- Mosher CE, Redd WH, Rini CM, Burkhalter JE, DuHamel KN. Physical, psychological, and social sequelae following hematopoietic stem cell transplantation: a review of the literature. *Psychooncology*. 2009;18(2):113-127.
- Mallack EJ, Turk B, Yan H, Eichler FS. The landscape of hematopoietic stem cell transplant and gene therapy for X-linked adrenoleukodystrophy. *Curr Treat Options Neurol.* 2019; 21(12):61.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.

How to cite this article: Gupta AO, Nascene DR, Shanley R, et al. Differential outcomes for frontal versus posterior demyelination in childhood cerebral adrenoleukodystrophy. *J Inherit Metab Dis.* 2021;44(6):1434-1440. doi:10.1002/jimd.12435